444902-34-5

Usage

Uses

Used in Pharmaceutical Industry:
6-chloro-5-iodopyridin-3-ol is used as an intermediate in the synthesis of pharmaceuticals for its ability to modulate enzyme activity and receptor binding. This allows for the development of new drugs with potential therapeutic effects.
Used in Agrochemical Industry:
6-chloro-5-iodopyridin-3-ol is also used as an intermediate in the synthesis of agrochemicals, contributing to the development of new pesticides or other agricultural chemicals that can improve crop protection and yield.
Used in Drug Discovery and Development:
Due to its potential applications in drug discovery and development, 6-chloro-5-iodopyridin-3-ol is utilized in research to explore its properties and identify new therapeutic targets, potentially leading to the creation of innovative medications.
Used in Antioxidant Research:
6-chloro-5-iodopyridin-3-ol has been studied for its antioxidant properties, which could be harnessed in the development of treatments aimed at combating oxidative stress-related conditions.
Used in Cancer Research:
6-chloro-5-iodopyridin-3-ol has been investigated for its potential to inhibit the growth of certain cancer cells, making it a candidate for further research in oncology and the development of anticancer drugs.

InChI:InChI=1/C5H3ClINO/c6-5-4(7)1-3(9)2-8-5/h1-2,9H

Upstream product

• 444902-33-4 5-acetoxy-2-chloro-3-iodopyridine 
• 5418-51-9 5-nitro-2-hydroxypyridine 
• 25391-58-6 2-hydroxy-3-iodo-5-nitropyridine 
• 444902-32-3 5-amino-2-chloro-3-iodopyridine 
• 25391-60-0 2-chloro-3-iodo-5-nitropyridine 

Relevant academic research and scientific papers

Synthesis and evaluation of a novel series of 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)- 3-(2-(4-pyridinyl)vinyl)pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors

Reportedly, 2-[18F]fluoro-A-85380, 1, a promising radiotracer for imaging the nicotinic acetylcholine receptor (nAChR) by positron emission tomography (PET) in humans, exhibits slow penetration through the blood-brain barrier (BBB) due to its low lipophilicity. A ligand for nAChRs with greater lipophilicity than that of 1 would be potentially more favorable for PET imaging of nAChR due to its faster penetration through the BBB. Herein, a novel series of compounds has been developed based on the high affinity ligand for nAChRs, 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)- 3-(2-(4-pyridinyl)vinyl)pyridine, 3b. The in vitro binding affinities for the new series were found to be in the range of Ki = 9-331 pM. A molecular modeling study showed differences in the comformational profiles and the electronic properties of these compounds, which provides further insight into the structure-activity relationships at nAChR. Lipophilicities of the compounds 3b-6b have been found to be substantially higher than that of 1. As a result, compounds 3b-6b might exhibit a faster penetration through the BBB than the less lipophilic 1. The N-methyl derivatives 3b and 6b demonstrated very high affinities at nAChRs (Ki = 28 and 23 pM, respectively) and will be targets for development of 11CH3-labeled derivatives as radiotracers for PET imaging of nAChRs.